HMG-CoA reductase inhibiting substituted pryido (2,3-d) pyrimidines

US5075311A · kind A · utility

Assignee

• BAYER HEALTHCARE LLC · DE

Inventors

• Walter Hubsch · Wuppertal, DE
• Rolf Angerbauer · Wuppertal, DE
• Peter Fey · Wuppertal, DE
• Thomas Philipps · Cologne, DE
• Hilmar Bischoff · Wuppertal, DE
• Dieter Petzinna · Mülheim an der Ruhr, DE
• Delf Schmidt · Wuppertal, DE
• Gunter Thomas · Arese, IT

Key dates

• Filing date: Jan 2, 1990
• Grant date: Dec 24, 1991
• Expiry date: Jan 2, 2010

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

New substituted pyrido(2,3-d)pyrimidines of the formula ##STR1## can be prepared by reduction of corresponding pyrido(2,3-d)-pyrimidines which are substituted by a ketone radical, and subsequent hydrolysis, cyclization or hydrogenation. The new compounds can be used to inhibit HMG-CoA reductase.